Antisauvagine-30 TFA (aSvg-30 TFA) is a highly selective and competitive antagonist of CRF2 receptor peptidic. It shows a Kd of 1.4 nM and 150 nM for mCRFR2β and CRFR1, respectively.
RTC-30 is an optimized phenothiazine compound possessing potent anti-cancer properties. It is formulated with a hydroxylated linker (N) which enhances its oral bioavailability[1].